NBTX - Nanobiotix

-

$undefined

N/A

(N/A)

Nanobiotix NasdaqGS:NBTX Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Location: 60 rue de Wattignies, Paris, 75012, France | Website: https://www.nanobiotix.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

196.9M

Cash

49.74M

Avg Qtr Burn

-4.888M

Short % of Float

0.30%

Insider Ownership

0.00%

Institutional Own.

12.15%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NBTXR3 +/- Cetuximab Details
Head and neck cancer

Phase 3

Interim Update

JNJ-1900 (NBTXR3) Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

Phase 1/2

Data readout

RT + NBTXR3 Details
Cancer, Pancreatic cancer

Phase 1b

Data readout

NBTXR3 + Anti-PD-1 Details
Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1

Data readout

RT + NBTXR3 Details
Cancer, Non-small cell lung carcinoma

Phase 1

Data readout

Phase 1

Update